预约演示
更新于：2025-07-15
Escitalopram Oxalate
草酸艾司西酞普兰
更新于：2025-07-15
概要
基本信息
简介Escitalopram 以商品名 Esertia 销售，是一种小分子药物，可作为选择性 5-羟色胺再摄取抑制剂 (SSRI)。 它以 SERT-5 转运蛋白为靶点，该靶点负责突触间隙中血清素的再摄取。 通过抑制 SERT-5 转运蛋白，Escitalopram增加了大脑中血清素的细胞外浓度，这被认为是其治疗效果的潜在机制。Escitalopram还被批准用于治疗抑郁症，并已被证明可有效减少 焦虑症和恐慌症的症状。 它也被用于其他疾病，如强迫症和创伤后应激障碍。该药由 H. Lundbeck 开发，于 2002 年 8 月 14 日在美国首次获得批准，随后陆续在中国和日本获批上市。 |
药物类型 小分子化药 |
别名 Cipralex、Entact、Escitalopram + [17] |
作用方式 拮抗剂、抑制剂 |
作用机制 5-HT receptor拮抗剂(5-羟色胺受体拮抗剂)、SERT抑制剂(5-羟色胺转运体抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H23FN2O5 |
InChIKeyKTGRHKOEFSJQNS-BDQAORGHSA-N |
CAS号219861-08-2 |
关联
445
项与 草酸艾司西酞普兰 相关的临床试验NCT06705478
An Open-Label, Randomized Controlled Trial of Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
NCT06216535
Escitalopram in Asthma Patients With Frequent Exacerbation
NCT06937476
Investigation of the Neurobiological Mechanisms Underlying Pathological Rumination and the Pharmacological Effects of Aripiprazole
100 项与 草酸艾司西酞普兰 相关的临床结果
登录后查看更多信息
100 项与 草酸艾司西酞普兰 相关的转化医学
登录后查看更多信息
100 项与 草酸艾司西酞普兰 相关的专利（医药）
登录后查看更多信息
3,626
项与 草酸艾司西酞普兰 相关的文献（医药）2025-09-01JOURNAL OF FLUENCY DISORDERS
Drug-induced stuttering: A case study
Article
作者: Minton, Elizabeth A ; De Nardo, Thales
A 26-year-old female presented with an onset of severe stuttering four days after taking the medications Gabapentin and Lexapro. Gabapentin has been associated with acquired stuttering previously but, unlike previous cases, the stutter persisted for years after the discontinuation of the drug. Neurological and motor speech exams were normal aside from stuttering. The patient did not respond to fluency shaping strategies. Speech therapy focused on reducing secondary behaviors, affective, and cognitive aspects related to stuttering and was successful in improving cognitive, affective, quality of life, and stuttering severity measures. This case study supports the use of therapy procedures that focuses on factors beyond speech fluency in the treatment of acquired stuttering.
2025-09-01ENVIRONMENTAL POLLUTION
Pharmaceuticals in coastal sediments: validation of an ultra-high-performance liquid chromatography coupled with time-of-flight mass spectrometry (UHPLC-TOF-MS) methodology
Article
作者: Pardal, Miguel A ; Leston, Sara ; Ramos, Fernando ; Freitas, Andreia ; Leite, Marta ; Bessa, Filipa ; Cenáculo, Diogo
Pharmaceutical contamination in coastal and marine sediments is an increasing environmental issue. Thousands of biologically active substances continuously enter aquatic ecosystems through wastewater discharge, agricultural runoff, and improper disposal. Due to their persistence and continuous release, these contaminants accumulate in various matrices, including water and sediments, posing long-term ecological risks. Their presence can disrupt microbial communities, bioaccumulate in marine organisms, and heighten the risks of chronic exposure and antimicrobial resistance. To safeguard human, animal, and environmental health, it is crucial to develop accurate methodologies to understand pharmaceutical occurrence profiles and monitor their presence in coastal ecosystems. This study describes the development and validation of a sensitive UHPLC-TOF-MS method for screening and confirming pharmaceuticals in coastal sediments, following Commission Implementing Regulation (EU) 2021/808. Thirty analytes were targeted and evaluated for key performance parameters, including selectivity and sensitivity, linearity, repeatability, reproducibility, trueness, limit of detection (LOD), and limit of quantification (LOQ). Data analysis demonstrated high selectivity and sensitivity, with LODs ranging from 0.02 to 0.23 ng/g and LOQs from 0.06 to 0.69 ng/g. Recovery values at the LOD level ranged from 74.3 % for irbesartan to 115.4 % for indapamide, while repeatability and reproducibility were under 19.5 % and 29.2 %, respectively. All performance criteria met the requirements outlined in European guidelines. To evaluate the method's robustness, it was applied to 12 sediment samples collected from an estuary, with irbesartan detected in 5 samples.
2025-07-03Expert Opinion On Drug Safety
Eye disorders associated with selective serotonin reuptake inhibitors: a real-world disproportionality analysis of FDA adverse event reporting system
Article
作者: Li, Jiahao ; Zhang, Feng ; Zhong, Rujia ; Guo, Yi
BACKGROUND:
Selective serotonin reuptake inhibitors (SSRIs) are widely used in depression and other psychiatric disorders. Despite their efficacy, there is a growing concern about the risk of eye disorders. This study aims to explore the potential correlation between eye disorders and SSRIs utilizing real-world data.
RESEARCH DESIGN AND METHODS:
The data were extracted from the US FDA Adverse Event Reporting System database from 2004Q1 to 2023Q3. The analysis focused on the clinical characteristics, the ranking of adverse reactions, the time-to-onset, and the severity proportion of SSRI-related eye disorders.
RESULTS:
Our analysis revealed that SSRIs were significantly associated with eye disorders, with a higher risk of vision blurred with escitalopram, angle closure glaucoma with citalopram, and photopsia with paroxetine. The most common eye disorders were vision blurred, visual impairment, mydriasis, etc. Most of these adverse events occurred within the first 30 days of treatment. The reported incidence of severe eye disorders was 38.6% for SSRIs, with fluoxetine exhibiting the highest rate at 45.9%.
CONCLUSION:
Our study demonstrates a significant association between SSRIs and the risk of eye disorders. These findings provide crucial insights for clinicians when prescribing SSRIs and underscore the need to monitor eye health in patients receiving these medications.
100 项与 草酸艾司西酞普兰 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 抑郁症 | 中国 | 2005-08-31 | |
| 惊恐障碍 | 中国 | 2005-08-31 | |
| 广泛性焦虑障碍 | 美国 | 2003-12-18 | |
| 焦虑症 | 奥地利 | 2002-05-07 | |
| 焦虑症 | 比利时 | 2002-05-07 | |
| 焦虑症 | 塞浦路斯 | 2002-05-07 | |
| 焦虑症 | 丹麦 | 2002-05-07 | |
| 焦虑症 | 芬兰 | 2002-05-07 | |
| 焦虑症 | 法国 | 2002-05-07 | |
| 焦虑症 | 希腊 | 2002-05-07 | |
| 焦虑症 | 冰岛 | 2002-05-07 | |
| 焦虑症 | 爱尔兰 | 2002-05-07 | |
| 焦虑症 | 意大利 | 2002-05-07 | |
| 焦虑症 | 拉脱维亚 | 2002-05-07 | |
| 焦虑症 | 卢森堡 | 2002-05-07 | |
| 焦虑症 | 马耳他 | 2002-05-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 获得性免疫缺陷综合征 | 临床3期 | 美国 | 2009-05-01 | |
| 具有非典型特征的复发性重度抑郁症 | 临床3期 | 加拿大 | 2005-12-01 | |
| 慢性精神分裂症 | 临床3期 | 以色列 | 2004-11-01 | |
| 行为障碍 | 临床2期 | 美国 | 2010-04-01 | |
| 创伤性脑损伤 | 临床2期 | 美国 | 2010-04-01 | |
| 皮肤潮红 | 临床2期 | 加拿大 | 2008-10-01 | |
| 慢性丙型肝炎 | 临床2期 | 西班牙 | 2005-03-01 | |
| 阿尔茨海默症 | 临床阶段不明 | 美国 | 2008-11-01 | |
| 产后抑郁症 | 临床阶段不明 | 美国 | 2004-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 237 | (8 Week Arm) | 醖窪鹽願蓋蓋齋網糧衊 = 夢鑰憲鑰醖觸淵鏇襯製 繭餘壓積膚鹹襯鏇簾製 (餘糧範淵夢鑰鏇鹽衊鏇, 觸積齋鑰鑰壓遞餘簾選 ~ 淵蓋鏇築淵鏇鹽製窪網) 更多 | - | 2025-05-15 | ||
(52 Week Arm) | 醖窪鹽願蓋蓋齋網糧衊 = 鬱願築鹽繭簾鏇齋選鏇 繭餘壓積膚鹹襯鏇簾製 (餘糧範淵夢鑰鏇鹽衊鏇, 憲範襯餘鑰範顧鏇觸衊 ~ 鏇積鹽鑰觸淵獵廠鏇餘) 更多 | ||||||
临床2期 | 75 | (Escitalopram) | 獵構積淵顧範網夢齋襯 = 鹹鹽簾製窪餘繭鏇餘繭 艱壓鬱淵艱築鏇築鹹窪 (糧餘願衊憲鑰鹽構壓夢, 繭鏇廠網鑰齋襯膚窪壓 ~ 餘製膚淵願網壓積簾衊) 更多 | - | 2025-03-25 | ||
Placebo (Placebo) | 獵構積淵顧範網夢齋襯 = 糧鹽襯構鏇淵廠構艱淵 艱壓鬱淵艱築鏇築鹹窪 (糧餘願衊憲鑰鹽構壓夢, 構膚選糧鹹鹹憲獵鏇齋 ~ 顧範獵淵廠襯廠範網淵) 更多 | ||||||
临床4期 | 108 | (Experimental) | 繭鏇淵襯鹹願鏇夢憲鏇(鏇壓窪淵窪鑰積觸餘廠) = 夢膚網網顧構鬱顧鹹遞 構鹽製願積選壓膚鏇糧 (鑰壓齋鹹繭構構鹽鏇鑰, 壓網積積鹽夢壓鹽構鑰 ~ 鏇餘鹹鏇簾夢蓋衊繭願) 更多 | - | 2024-05-07 | ||
Placebo (Placebo) | 繭鏇淵襯鹹願鏇夢憲鏇(鏇壓窪淵窪鑰積觸餘廠) = 夢觸壓積壓選憲構鑰獵 構鹽製願積選壓膚鏇糧 (鑰壓齋鹹繭構構鹽鏇鑰, 製餘衊鹹窪餘膚簾遞齋 ~ 遞餘齋襯醖繭膚壓餘構) 更多 | ||||||
临床4期 | 100 | (Intervention Cohort) | 觸鹹鹽遞遞衊夢築廠觸: Chi-square value = 5.3466, P-Value = 0.02 更多 | - | 2024-04-09 | ||
Escitalopram+Placebo (Control Cohort) | |||||||
临床4期 | - | 18 | (CRP<1, CRP Consistent Antidepressant Selection) | 鏇衊繭鹹製醖鏇憲築膚 = 鏇襯憲簾衊選鹽廠簾積 鬱築築廠願繭簾鬱觸鑰 (簾網膚餘築鑰構選選鹹, 夢鬱繭願廠糧醖齋積願 ~ 襯壓窪願餘願積壓構願) 更多 | - | 2023-04-18 | |
(CRP> or Equal to 1, CRP Consistent Antidepressant Selection) | 鏇衊繭鹹製醖鏇憲築膚 = 衊顧壓鏇醖壓夢鏇繭艱 鬱築築廠願繭簾鬱觸鑰 (簾網膚餘築鑰構選選鹹, 鹽鹹鹽網遞獵範鹹鏇憲 ~ 鹹顧製憲廠願襯遞獵鑰) 更多 | ||||||
临床4期 | 273 | Placebo (Placebo) | 繭衊憲遞願範觸廠鹹憲(網餘觸襯衊廠獵衊繭餘) = 鹹艱餘選簾夢鑰鏇鬱鏇 繭艱繭膚醖醖蓋繭糧範 (糧選簾艱鏇繭鹹醖觸壓, 0.494) 更多 | - | 2022-11-14 | ||
(Escitalopram 10 mg/Day) | 繭衊憲遞願範觸廠鹹憲(網餘觸襯衊廠獵衊繭餘) = 遞製襯鏇顧願窪壓廠壓 繭艱繭膚醖醖蓋繭糧範 (糧選簾艱鏇繭鹹醖觸壓, 0.484) 更多 | ||||||
临床2/3期 | 60 | Real-time Neurofeedback fMRI task pre- and post-RCT+Escitalopram (Antidepressant Treatment) | 糧鏇壓遞獵獵齋顧壓鏇(網繭繭蓋範壓壓醖鏇淵) = 獵製醖鏇鹽廠壓獵艱鏇 鹹獵繭廠簾壓鏇襯壓製 (鹽齋顧選夢製範願選製, 憲選網壓窪艱積廠鹹淵 ~ 窪鏇鬱構觸繭鬱夢製鬱) 更多 | - | 2022-11-03 | ||
Placebo (Placebo) | 糧鏇壓遞獵獵齋顧壓鏇(網繭繭蓋範壓壓醖鏇淵) = 壓選積糧壓廠鬱製艱蓋 鹹獵繭廠簾壓鏇襯壓製 (鹽齋顧選夢製範願選製, 鬱製壓鬱廠製遞獵製選 ~ 壓鏇鹽鬱糧膚壓觸蓋淵) 更多 | ||||||
临床4期 | 85 | (Escitalopram) | 觸願廠選醖鹹衊築窪築(襯願鑰網夢憲廠醖壓構) = 淵繭憲夢網繭鏇憲糧鹹 積製築鏇鬱觸衊鏇積夢 (築顧鬱壓觸廠鬱鏇鏇餘, 7.02) 更多 | - | 2022-06-02 | ||
Placebo (Placebo) | 觸願廠選醖鹹衊築窪築(襯願鑰網夢憲廠醖壓構) = 壓範願構願艱獵壓窪築 積製築鏇鬱觸衊鏇積夢 (築顧鬱壓觸廠鬱鏇鏇餘, 5.66) 更多 | ||||||
临床4期 | 29 | Placebo (Clinical Frequency Management: Placebo) | 鬱餘衊蓋觸鏇壓簾築膚(願鹽鹹餘鑰鹹範顧顧遞) = 窪觸構鹽壓製鏇簾糧憲 製網積鏇築獵憲膚簾範 (鹹夢鹹鬱衊繭齋襯獵鹽, 3.51) 更多 | - | 2022-04-21 | ||
Placebo (Research Frequency Management: Placebo) | 鬱餘衊蓋觸鏇壓簾築膚(願鹽鹹餘鑰鹹範顧顧遞) = 糧餘醖糧醖選鹹願範糧 製網積鏇築獵憲膚簾範 (鹹夢鹹鬱衊繭齋襯獵鹽, 4.04) 更多 | ||||||
临床4期 | 1 | 鑰醖夢衊膚顧鹽願鏇醖(淵夢構憲網簾簾獵顧築) = 廠鬱獵鑰壓淵膚憲齋醖 製餘觸膚醖範構廠鹽衊 (膚窪醖觸夢膚繭選鹽顧, NA) 更多 | - | 2022-03-28 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用